Healthcare Distribution Alliance – Patients Move Us.
Share Print
blog banner

HDA Blog

Blog Entries

Davis Spotlights HDA's 2021 Strategic Priorities


HDA will be carrying forward the early lessons learned from COVID-19 pandemic and supporting response efforts in 2021, writes President and CEO Chip Davis in the January 4 issue of Chain Drug Review — particularly as distributors play a role in the largest public vaccination effort in recent memory. Davis provided his perspective on the year ahead, along with other healthcare trade association leaders, as part of the publication’s 2021 “Pharmacy Outlook” feature.


DSCSA, the 2023 Requirements and EPCIS

Posted by Anita T. Ducca

Since the enactment of the Drug Supply Chain Security Act in 2013, members of the pharmaceutical supply chain have undertaken efforts to meet each of the major milestones contained within the statute’s 10-year timeline to further secure the safety of the products being distributed. The industry’s progress to 2023 interoperability was top of mind as supply chain and other stakeholders came together at HDA’s recent Traceability Online Seminar.


Leveraging Public and Private Sector Collaboration to Respond to COVID-19


While it has only been a few months since the first American was diagnosed with COVID-19, the scope of the pandemic is one which we have never experienced before. Throughout, it has become abundantly clear that our nation’s ability to effectively respond to this once-in-a-lifetime crisis depends on the public and private sectors joining forces, maintaining constant coordination, and working together to identify operational and regulatory barriers impeding access to medicines and medical supplies.


DSCSA Saleable Returns: Industry Plan for Best Using the Enforcement Discretion Period

Posted by Justine Freisleben

It has been clear for some time that the pharmaceutical supply chain has been concerned with meeting the November 27, 2019, saleable returns milestone. As the HDA’s Research Foundation’s annual Serialization Readiness Survey (conducted in May) notes, 79 percent of manufacturers have concerns with the viability of the Verification Router Service (VRS), while 82 percent of distributors are unsure about meeting the requirement.


HDA Traceability Seminar to Feature FDA Update, Discussions on DSCSA Milestones

Posted by Perry L. Fri

As the summer winds down, HDA is hard at work planning our 2018 Traceability Seminar, which will take place three weeks earlier, on October 17–19 at the Renaissance Washington, DC Downtown Hotel. As the industry passes the halfway mark for DSCSA implementation, our 2018 agenda leverages HDA and our members’ unique expertise to help fellow stakeholders answer critical questions while planning for the multiple milestones ahead.

View more
© 2020 Healthcare Distribution Alliance. All rights reserved.
HDA: E | C | C2 | NF | O365